DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ovarian dysgenesis 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian dysgenesis 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian dysgenesis 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Three surgical techniques for orthotopic ovarian transplant are described in a 2006 review of three cases, with ovarian dysgenesis listed as one indication alongside premature ovarian failure and fertility preservation in cancer patients. No survival or response data are given; the report is a technical description, not a trial.
A 2025 review article discusses drug repositioning for ovarian cancer therapy, citing in vitro experiments across cancer cell lines and preclinical in vivo models. The review mentions potential synergies with other drugs but provides no concrete numbers — no response rates, no survival data, no sample sizes. It is a forward-looking summary of a strategy, not a report of clinical results.
A 2022 mouse study found that Lhx9 haploinsufficiency (Lhx9 +/-) caused subfertility and altered ovarian transcription. RNA-sequencing identified 90 differentially expressed genes compared to wild-type mice. Gene ontology showed downregulation of steroidogenesis genes and upregulation of genes linked to ovarian cancer. The ovarian epithelium was disorganised with increased epithelial marker expression. No human data are presented; the work is in a knockout mouse model.
A 2017 Russian-language paper argues that different morphological subtypes of ovarian cancer have different courses and prognoses, and attempts to build a logical model of pathogenesis. No drug, no trial, no patient data are reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Transplantation · 2006 · 19 citations · open access
Orthotopic ovarian transplant – review and three surgical techniques
AbstractTransplantation of organs is a rapidly expanding faculty of medicine. While the solid organ transplantation has grown by leaps and bounds, ovarian transplantation is still in its infancy. Although recent interest has been generated for preservation of fertility in cancer therapy patients, other indications have emerged. Ovarian dysgenesis with missing normal ovarian complement and premature ovarian failure has come in the forefront. Three cases of orthotopic ovarian transplant with different surgical techniques have been described along with a brief overview.
Frontiers in Oncology · 2025 · 7 citations · open access
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
AbstractDrug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough in vitro experiments across diverse cancer cell lines, which are validated through preclinical in vivo models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.
bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 0 citations
Lhx9 haploinsufficiency alters transcription in the adult mouse ovary, causing subfertility and abnormal epithelium
AbstractAbstract Understanding the molecular pathways that underpin ovarian development and function is vital for improving the research approaches to investigating fertility. Despite a significant improvement in our knowledge of molecular activity in the ovary, many questions remain unanswered in the quest to understand factors influencing fertility and ovarian pathologies such as cancer. Here we present an investigation into the expression and function of developmental transcription factor LIM Homeobox 9 (LHX9) in the adult mouse ovary. We have characterised Lhx9 expression in several cell types of the mature ovary across follicle stages. To elucidate the function of this expression, we carried out an investigation of ovarian anatomy and transcription in a Lhx9 +/- knockout mouse model displaying subfertility. Despite a lack of gross anatomical differences between genotypes, RNA-sequencing found that 90 genes were differentially expressed between Lhx9 +/- and Lhx9 +/+ mice. Gene ontology analyses revealed a downregulation of genes with major roles in ovarian steroidogenesis and an upregulation of genes with implications for ovarian cancer. Analysis of the ovarian epithelium revealed Lhx9 +/- mice have a disorganised epithelial phenotype and a significant increase in epithelial marker gene expression. These results provide an analysis of Lhx9 in the adult mouse ovary and a new candidate for fertility research and ovarian epithelial cancer. Summary sentence Lhx9 haploinsufficient mice are subfertile with altered expression of steroid genes in the adult ovary and abnormal ovarian surface epithelium.
Рак яичников: новый взгляд и патогенетические варианты
AbstractRecent years, our knowledge concerning pathogenesis and molecular processes initiation that take place in different tumor subtypes, greatly multiplied. And although clinically ovarian cancer is one disease, scientists are increasingly talking about the fact that different morphological subtypes have different course and prognosis. In the present study, in terms of the array of facts an attempt to build the closest logically grounded model of ovarian cancer pathogenesis was made. It had to be able to reflect variants of ovarian cancer clinical manifestation and predetermine the most promising ways of further scientific research to solve gynecological oncology topical issues.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
